AR098261A2 - Composición de liberación controlada y método para producirla - Google Patents
Composición de liberación controlada y método para producirlaInfo
- Publication number
- AR098261A2 AR098261A2 ARP140104096A ARP140104096A AR098261A2 AR 098261 A2 AR098261 A2 AR 098261A2 AR P140104096 A ARP140104096 A AR P140104096A AR P140104096 A ARP140104096 A AR P140104096A AR 098261 A2 AR098261 A2 AR 098261A2
- Authority
- AR
- Argentina
- Prior art keywords
- controlled release
- salt
- produce
- composition
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Lubricants (AREA)
- Moulds For Moulding Plastics Or The Like (AREA)
Abstract
Una composición de liberación controlada que comprende (1) un derivado de la LH-RH o una sal del mismo en una cantidad de aproximadamente el 3% (p/p) a aproximadamente el 24% (p/p) en base al peso total de la composición, y (2) un polímero compuesto solamente de ácido láctico o una sal del mismo que tiene un peso molecular medio en peso de 15000 a 50000 en donde el contenido de los polímeros que tienen pesos moleculares de 5000 o menos es de aproximadamente el 5% en peso o menos, y método para producir la misma. Reivindicación 6: La composición de liberación controlada de acuerdo con la reivindicación 1, caracterizada porque el derivado de la LH-RH es un péptido de la fórmula: 5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z [donde Y representa DLeu, DAla, DTrp, DSer(tBu), D2Nal o DHis(ImBzl), y Z representa NH-C₂H₅, o Gly-NH₂], o una sal del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001199484 | 2001-06-29 | ||
| JP2001340993 | 2001-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098261A2 true AR098261A2 (es) | 2016-05-18 |
Family
ID=26617910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102406A AR034641A1 (es) | 2001-06-29 | 2002-06-26 | Composicion de liberacion controlada y metodo para producirla |
| ARP140104096A AR098261A2 (es) | 2001-06-29 | 2014-11-03 | Composición de liberación controlada y método para producirla |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102406A AR034641A1 (es) | 2001-06-29 | 2002-06-26 | Composicion de liberacion controlada y metodo para producirla |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US7429559B2 (es) |
| EP (3) | EP1330293B2 (es) |
| JP (5) | JP2003206240A (es) |
| KR (2) | KR100916173B1 (es) |
| CN (3) | CN100577206C (es) |
| AR (2) | AR034641A1 (es) |
| AT (3) | ATE387937T1 (es) |
| AU (2) | AU2002311631B2 (es) |
| BR (1) | BRPI0210561B8 (es) |
| CA (1) | CA2455392C (es) |
| CO (1) | CO5540367A2 (es) |
| CR (1) | CR11283A (es) |
| CY (2) | CY1105071T1 (es) |
| CZ (1) | CZ306327B6 (es) |
| DE (2) | DE60225481T2 (es) |
| DK (2) | DK1949936T3 (es) |
| ES (2) | ES2263788T5 (es) |
| HK (1) | HK1056332A1 (es) |
| HU (1) | HU230351B1 (es) |
| IL (3) | IL159059A0 (es) |
| MX (1) | MXPA03011456A (es) |
| MY (1) | MY142066A (es) |
| NO (1) | NO331883B1 (es) |
| NZ (2) | NZ541884A (es) |
| PE (1) | PE20030066A1 (es) |
| PL (1) | PL204903B1 (es) |
| PT (2) | PT1949936E (es) |
| RU (1) | RU2301661C2 (es) |
| SG (1) | SG180015A1 (es) |
| SI (1) | SI1949936T1 (es) |
| SK (1) | SK287577B6 (es) |
| TW (2) | TWI332407B (es) |
| WO (1) | WO2003002092A2 (es) |
| ZA (1) | ZA200309152B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0100221A3 (en) * | 1998-01-16 | 2002-11-28 | Takeda Pharmaceutical | Sustained release compositions, process for producing the same and utilization thereof |
| TWI332407B (en) * | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
| TWI225416B (en) * | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
| ES2605402T3 (es) | 2002-06-25 | 2017-03-14 | Takeda Pharmaceutical Company Limited | Procedimiento para producir una composición de liberación sostenida |
| BRPI0409032A (pt) * | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
| US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| US8871269B2 (en) * | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
| CA2533592C (en) * | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| TW200529890A (en) * | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
| TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
| US20060251581A1 (en) * | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
| US20070149457A1 (en) * | 2005-12-13 | 2007-06-28 | Byron Rubin | Stable solid forms of enterostatin |
| CN101400363B (zh) | 2006-01-18 | 2012-08-29 | 昌达生物科技公司 | 具有增强的稳定性的药物组合物 |
| US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| BRPI0720582B1 (pt) | 2006-12-18 | 2021-08-24 | Takeda Pharmaceutical Company Limited | Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa |
| US20110319987A1 (en) * | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
| KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
| EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| CN103751851A (zh) * | 2014-01-17 | 2014-04-30 | 东华大学 | 一种无机/有机多药物控释复合纳米纤维支架的制备方法 |
| KR101558083B1 (ko) * | 2014-04-07 | 2015-10-07 | 에스케이케미칼주식회사 | 약물함유 고분자미립구 제조방법 |
| US9956164B2 (en) | 2014-04-16 | 2018-05-01 | Veyx-Pharma Gmbh | Veterinary pharmaceutical composition and use thereof |
| US10787920B2 (en) | 2016-10-12 | 2020-09-29 | General Electric Company | Turbine engine inducer assembly |
| KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
| WO2024095158A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3297033A (en) | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
| US3565869A (en) | 1968-12-23 | 1971-02-23 | American Cyanamid Co | Extrudable and stretchable polyglycolic acid and process for preparing same |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3755558A (en) | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
| US3839297A (en) | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
| US3912692A (en) | 1973-05-03 | 1975-10-14 | American Cyanamid Co | Process for polymerizing a substantially pure glycolide composition |
| US3890283A (en) | 1973-06-04 | 1975-06-17 | American Cyanamid Co | Process for post-polymerizing polyglycolic acid |
| US4258063A (en) | 1978-06-23 | 1981-03-24 | Henkel Corporation | Self-emulsifying cosmetic base |
| US4249531A (en) | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
| US4273920A (en) | 1979-09-12 | 1981-06-16 | Eli Lilly And Company | Polymerization process and product |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4479911A (en) | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
| US4605730A (en) | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
| US4539981A (en) | 1982-11-08 | 1985-09-10 | Johnson & Johnson Products, Inc. | Absorbable bone fixation device |
| FR2537980B1 (fr) | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| JPH0678425B2 (ja) | 1984-07-06 | 1994-10-05 | 和光純薬工業株式会社 | 重合体の新規製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| EP0190833B1 (en) | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| DE69129770T2 (de) * | 1990-04-13 | 1998-11-19 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| US5353086A (en) * | 1993-05-03 | 1994-10-04 | Eastman Kodak Company | Textured surface with canted channels for an automatic tray processor |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| JP3490171B2 (ja) | 1994-02-21 | 2004-01-26 | 武田薬品工業株式会社 | 生体内分解性ポリマーの末端カルボキシル基におけるエステル |
| DE69508985T2 (de) * | 1994-02-21 | 1999-08-19 | Takeda Chemical Industries Ltd | Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe |
| US5763513A (en) | 1994-05-19 | 1998-06-09 | Mitsui Toatsu Chemicals, Inc. | L-lactic acid polymer composition, molded product and film |
| JPH08259460A (ja) * | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| JP3902272B2 (ja) * | 1995-09-04 | 2007-04-04 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
| US5922662A (en) * | 1996-08-07 | 1999-07-13 | Colgate Palmolive Company | High foaming nonionic surfactant based liquid detergent |
| PT839525E (pt) * | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| WO1998032423A1 (en) | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
| HUP0100221A3 (en) * | 1998-01-16 | 2002-11-28 | Takeda Pharmaceutical | Sustained release compositions, process for producing the same and utilization thereof |
| JPH11269094A (ja) | 1998-01-16 | 1999-10-05 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| US6114495A (en) | 1998-04-01 | 2000-09-05 | Cargill Incorporated | Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| CN1134479C (zh) * | 1998-12-15 | 2004-01-14 | 武田药品工业株式会社 | 制备聚合物的方法 |
| JP2000238051A (ja) † | 1999-02-23 | 2000-09-05 | Kansei Corp | 表皮シートの発泡成形型へのセッティング方法 |
| AU5853000A (en) * | 1999-07-15 | 2001-02-05 | Takeda Chemical Industries Ltd. | Sustained release compositions, process for producing the same and use thereof |
| JP2001081043A (ja) * | 1999-07-15 | 2001-03-27 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| JP3837607B2 (ja) † | 2000-05-29 | 2006-10-25 | Ｔｃｍ株式会社 | マスト用溶接位置決め治具 |
| ES2256276T5 (es) | 2000-08-07 | 2011-02-22 | Wako Pure Chemical Industries, Ltd. | Polímero de ácido láctico y procedimiento para su producción. |
| AU2002218494A1 (en) * | 2000-11-29 | 2002-06-11 | Takeda Chemical Industries Ltd. | Medicinal compositions and process for producing the same |
| WO2002047722A1 (fr) * | 2000-12-15 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions |
| TWI332407B (en) * | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
-
2002
- 2002-06-26 TW TW091114000A patent/TWI332407B/zh not_active IP Right Cessation
- 2002-06-26 TW TW094113186A patent/TW200526267A/zh unknown
- 2002-06-26 AR ARP020102406A patent/AR034641A1/es not_active Application Discontinuation
- 2002-06-27 PE PE2002000578A patent/PE20030066A1/es active IP Right Grant
- 2002-06-28 SK SK1560-2003A patent/SK287577B6/sk unknown
- 2002-06-28 IL IL15905902A patent/IL159059A0/xx unknown
- 2002-06-28 AT AT04076939T patent/ATE387937T1/de not_active IP Right Cessation
- 2002-06-28 AU AU2002311631A patent/AU2002311631B2/en not_active Expired
- 2002-06-28 MX MXPA03011456A patent/MXPA03011456A/es active IP Right Grant
- 2002-06-28 CA CA2455392A patent/CA2455392C/en not_active Expired - Fee Related
- 2002-06-28 EP EP02738838A patent/EP1330293B2/en not_active Expired - Lifetime
- 2002-06-28 HU HU0400378A patent/HU230351B1/hu unknown
- 2002-06-28 CN CN200610093268A patent/CN100577206C/zh not_active Expired - Fee Related
- 2002-06-28 DE DE60225481T patent/DE60225481T2/de not_active Expired - Lifetime
- 2002-06-28 BR BRPI0210561-6 patent/BRPI0210561B8/pt not_active IP Right Cessation
- 2002-06-28 CN CNB028130618A patent/CN1292796C/zh not_active Expired - Lifetime
- 2002-06-28 AT AT02738838T patent/ATE326264T1/de active
- 2002-06-28 JP JP2002189247A patent/JP2003206240A/ja active Pending
- 2002-06-28 DK DK08003261.8T patent/DK1949936T3/da active
- 2002-06-28 US US10/182,731 patent/US7429559B2/en not_active Expired - Fee Related
- 2002-06-28 SI SI200230949T patent/SI1949936T1/sl unknown
- 2002-06-28 PT PT08003261T patent/PT1949936E/pt unknown
- 2002-06-28 PT PT02738838T patent/PT1330293E/pt unknown
- 2002-06-28 KR KR1020037017129A patent/KR100916173B1/ko active IP Right Grant
- 2002-06-28 ES ES02738838T patent/ES2263788T5/es not_active Expired - Lifetime
- 2002-06-28 EP EP04076939A patent/EP1491236B1/en not_active Expired - Lifetime
- 2002-06-28 CN CNB2005100896706A patent/CN100348265C/zh not_active Expired - Fee Related
- 2002-06-28 SG SG2005085675A patent/SG180015A1/en unknown
- 2002-06-28 MY MYPI20022474A patent/MY142066A/en unknown
- 2002-06-28 RU RU2004102507/15A patent/RU2301661C2/ru active
- 2002-06-28 NZ NZ541884A patent/NZ541884A/en not_active IP Right Cessation
- 2002-06-28 CZ CZ2003-3493A patent/CZ306327B6/cs not_active IP Right Cessation
- 2002-06-28 PL PL367518A patent/PL204903B1/pl unknown
- 2002-06-28 DE DE60211464T patent/DE60211464T3/de not_active Expired - Lifetime
- 2002-06-28 KR KR1020097001485A patent/KR100961413B1/ko not_active IP Right Cessation
- 2002-06-28 WO PCT/JP2002/006527 patent/WO2003002092A2/en active Application Filing
- 2002-06-28 NZ NZ529969A patent/NZ529969A/en not_active IP Right Cessation
- 2002-06-28 ES ES08003261T patent/ES2366677T3/es not_active Expired - Lifetime
- 2002-06-28 EP EP08003261A patent/EP1949936B1/en not_active Expired - Lifetime
- 2002-06-28 AT AT08003261T patent/ATE509668T1/de active
- 2002-06-28 DK DK02738838.8T patent/DK1330293T4/da active
-
2003
- 2003-11-25 IL IL159059A patent/IL159059A/en active IP Right Grant
- 2003-11-25 ZA ZA2003/09152A patent/ZA200309152B/en unknown
- 2003-11-27 HK HK03108668A patent/HK1056332A1/xx not_active IP Right Cessation
- 2003-12-19 NO NO20035738A patent/NO331883B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111729A patent/CO5540367A2/es active IP Right Grant
-
2004
- 2004-04-13 JP JP2004117981A patent/JP2004238400A/ja not_active Withdrawn
-
2006
- 2006-07-07 CY CY20061100943T patent/CY1105071T1/el unknown
- 2006-12-01 AU AU2006246508A patent/AU2006246508B2/en not_active Ceased
-
2007
- 2007-10-18 IL IL186782A patent/IL186782A0/en unknown
-
2008
- 2008-07-29 US US12/181,472 patent/US8067030B2/en not_active Expired - Fee Related
-
2009
- 2009-03-18 JP JP2009065612A patent/JP2009167203A/ja not_active Withdrawn
-
2010
- 2010-02-18 CR CR11283A patent/CR11283A/es unknown
- 2010-04-26 JP JP2010101264A patent/JP4819172B2/ja not_active Expired - Lifetime
- 2010-04-26 JP JP2010101265A patent/JP4819173B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-16 US US13/064,282 patent/US8246987B2/en not_active Expired - Lifetime
- 2011-07-15 CY CY20111100692T patent/CY1111708T1/el unknown
-
2012
- 2012-07-13 US US13/548,463 patent/US8815801B2/en not_active Expired - Lifetime
-
2014
- 2014-11-03 AR ARP140104096A patent/AR098261A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098261A2 (es) | Composición de liberación controlada y método para producirla | |
| PE20030069A1 (es) | Composicion de liberacion sostenida y proceso para producirla | |
| CY1118798T1 (el) | Συνθεση της διαδερμικης παροχης φαιντανυλης | |
| BR0002671A (pt) | Composição adesiva dental | |
| CY1105286T1 (el) | Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης | |
| RS51271B (sr) | Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid | |
| CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
| AR045937A1 (es) | Modulacion de la expresion del factor de iniciacion eucariotico eif4e | |
| CY1110602T1 (el) | Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους | |
| BR0114994A (pt) | Composição de vacina | |
| BR0208183A (pt) | Peptìdeo modificado por wt1 | |
| CY1107644T1 (el) | Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης | |
| CY1107738T1 (el) | Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης | |
| ES2050070B1 (es) | Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. | |
| ATE291737T1 (de) | Screening-assays unter verwendung von intramitochondrialem kalzium | |
| CY1106634T1 (el) | Θεραπευτικα παραγωγα της πιπεραζινης | |
| CO5570652A2 (es) | Productos en gel para la axila, con componente de bloqueo de agua | |
| CY1105559T1 (el) | Φαρμακευτικες συνθεσεις του tegaserod | |
| ATE437647T1 (de) | Transporter mit beabstandeten arginin-teilchen | |
| AR013592A1 (es) | Composiciones de modelado capilar | |
| EP2260835A3 (en) | Composition for proteasome inhibition | |
| ES2188214T3 (es) | Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico. | |
| BR0316437A (pt) | Composição cosmeticamente aceitável para tratamento da pele, e, método para tratar a pele | |
| BRPI0514411A (pt) | formulação, e, método de produzir uma formulação | |
| JP2003206240A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |